73
Views
42
CrossRef citations to date
0
Altmetric
Original Article

Is There Any Difference in PBPC Mobilization Between Cyclophosphamide Plus G-CSF and G-CSF Alone in Patients with Non-Hodgkin's Lymphoma?

, , , , , , , , , , , & show all
Pages 301-310 | Accepted 20 May 2000, Published online: 01 Jul 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Adebayo Ogunniyi, Mabel Rodriguez, Sean Devlin, Nelly Adel, Heather Landau, David J. Chung, Nikoletta Lendvai, Alexander Lesokhin, Guenther Koehne, Sham Mailankody, Neha Korde, Lilian Reich, Ola Landgren, Sergio Giralt & Hani Hassoun. (2017) Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiency*. Leukemia & Lymphoma 58:5, pages 1123-1129.
Read now
Saad Akhtar, Amr El Weshi, Mohemmed Rahal, Yasser Khafaga, Abdelghani Tbakhi, Hind Humaidan & Irfan Maghfoor. (2008) Factors affecting autologous peripheral blood stem cell collection in patients with relapsed or refractory diffuse large cell lymphoma and Hodgkin lymphoma: A single institution result of 168 patients. Leukemia & Lymphoma 49:4, pages 769-778.
Read now

Articles from other publishers (40)

Ahmet Sarici, Mehmet Ali Erkurt, Irfan Kuku, Selim Gok, Omer Faruk Bahcecioglu, Soykan Bicim, Ilhami Berber, Emin Kaya & Mustafa Ozgul. (2021) Selection of the mobilization regimen in lymphoma patients: A retrospective cohort study. Transfusion and Apheresis Science 60:5, pages 103251.
Crossref
Mohamed L. Salem, Enas A. Abdul B, Abdel-Aziz A. Zidan & Rehab M. Elghara. (2020) Stem Cell Mobilization with G-CSF and Cyclophosphamide Ameliorated Collagen-Induced Arthritis in Wistar Rats. International Journal of Pharmacology 16:3, pages 223-235.
Crossref
Katharina Kriegsmann & Patrick Wuchter. 2019. Stem Cell Mobilization. Stem Cell Mobilization 41 58 .
So Yeon Jeon, Ho-Young Yhim, Hee Sun Kim, Jeong-A Kim, Deok-Hwan Yang & Jae-Yong Kwak. (2018) The effect of the dexamethasone, cytarabine, and cisplatin (DHAP) regimen on stem cell mobilization and transplant outcomes of patients with non-Hodgkin’s lymphoma who are candidates for up-front autologous stem cell transplantation. The Korean Journal of Internal Medicine 33:6, pages 1169-1181.
Crossref
Mehmet Hilmi Dogu, Hikmetullah Batgi, Mehmet Ali Erkurt, Sibel Hacioglu, Emre Tekgunduz, Emin Kaya, Dicle Iskender, Rafet Eren, Irfan Kuku & Fevzi Altuntas. (2018) Stem cell mobilization kinetics in elderly patients with multiple myeloma. Transfusion and Apheresis Science 57:2, pages 204-207.
Crossref
Sinem Namdaroglu, Serdal Korkmaz & Fevzi Altuntas. (2017) Management of mobilization failure in 2017. Transfusion and Apheresis Science 56:6, pages 836-844.
Crossref
Rajiv Kumar, Rajan Kapoor, Bhushan Asthana, Jasjit Singh, Tarun Verma, Rajesh Chilaka, N. K. Singh, Ajay Sharma, S. Das & Velu Nair. (2017) Single Dose Preemptive Plerixafor for Stem Cell Mobilization for ASCT After Lenalidomide Based Therapy in Multiple Myeloma: Impact in Resource Limited Setting. Indian Journal of Hematology and Blood Transfusion 33:4, pages 463-469.
Crossref
Shan YuanShirong Wang. (2016) How do we mobilize and collect autologous peripheral blood stem cells?. Transfusion 57:1, pages 13-23.
Crossref
D J Green, W I Bensinger, L A Holmberg, T Gooley, B G Till, L E Budde, J M Pagel, S L Frayo, J E Roden, L Hedin, O W Press & A K Gopal. (2016) Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myeloma. Bone Marrow Transplantation 51:10, pages 1330-1336.
Crossref
Mehmet Hilmi Dogu, Ali Hakan Kaya, Ilhami Berber, İsmail Sari, Emre Tekgündüz, Mehmet Ali Erkurt, Dicle Iskender, Ömur Kayıkçı, Irfan Kuku, Emin Kaya, Ali Keskin & Fevzi Altuntaş. (2016) Does the preference of peripheral versus central venous access in peripheral blood stem cell collection/yield change stem cell kinetics in autologous stem cell transplantation?. Transfusion and Apheresis Science 54:1, pages 76-79.
Crossref
Marco Aurélio Salvino & Jefferson Ruiz. (2016) Hematopoietic progenitor cell mobilization for autologous transplantation – a literature review. Revista Brasileira de Hematologia e Hemoterapia 38:1, pages 28-36.
Crossref
Antony F. Cousins, Joy E. Sinclair, Michael J Alcorn, Rachel H.A. Green & Kenny W. Douglas. (2015) HPC‐A dose prediction on the optia® cell separator based on a benchmark CE2 collection efficiency: Promoting clinical efficiency, minimizing toxicity, and allowing quality control. Journal of Clinical Apheresis 30:6, pages 321-328.
Crossref
Hakan Goker, Sezgin Etgul & Yahya Buyukasik. (2015) Optimizing mobilization strategies in difficult-to-mobilize patients: The role of plerixafor. Transfusion and Apheresis Science 53:1, pages 23-29.
Crossref
Sinem Civriz Bozdag & Osman Ilhan. (2015) Peripheral blood stem cell mobilization and collection from elderly patients and elderly healthy donor. Transfusion and Apheresis Science 53:1, pages 8-12.
Crossref
Sergio Giralt, Luciano Costa, Jeffrey Schriber, John DiPersio, Richard Maziarz, John McCarty, Paul Shaughnessy, Edward Snyder, William Bensinger, Edward Copelan, Chitra Hosing, Robert Negrin, Finn Bo Petersen, Damiano Rondelli, Robert Soiffer, Helen Leather, Amy Pazzalia & Steven Devine. (2014) Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations. Biology of Blood and Marrow Transplantation 20:3, pages 295-308.
Crossref
Sibel Hacıoğlu, Ismail Sarı, Mehmet Hilmi Doğu & Ali Keskin. (2014) The effect of gradual increment in rhG-CSF dose on stem cell yields in patients with multiple myeloma mobilized with intermediate dose cyclophosphamide plus rhG-CSF. Transfusion and Apheresis Science 50:1, pages 71-74.
Crossref
Aleš Tichopád, Veronika Vítová, Zdeněk Kořístek & Daniel Lysák. (2013) Cost‐effectiveness of hematopoietic stem cell mobilization strategies including plerixafor in multiple myeloma and lymphoma patients. Journal of Clinical Apheresis 28:6, pages 395-403.
Crossref
A D Sung, D T Grima, L M Bernard, S Brown, G Carrum, L Holmberg, M E Horwitz, J L Liesveld, J Kanda, B McClune, P Shaughnessy, G J Tricot & N J Chao. (2013) Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF vs G-CSF alone. Bone Marrow Transplantation 48:11, pages 1444-1449.
Crossref
Sinem Civriz Bozda?Emre Tekg?nd?z, Gamze Durgun, Abdurrahman Sar?ca, It?r ?irino?lu Demiriz, ?erife Ko?ubaba & Fevzi Altunta?. (2013) Which regimen is better for stem cell mobilization of lymphoma patients?. Transfusion and Apheresis Science 48:3, pages 407-410.
Crossref
P. Alvarez, E. Carrillo, C. Vélez, F. Hita-Contreras, A. Martínez-Amat, F. Rodríguez-Serrano, H. Boulaiz, R. Ortiz, C. Melguizo, J. Prados & A. Aránega. (2013) Regulatory Systems in Bone Marrow for Hematopoietic Stem/Progenitor Cells Mobilization and Homing. BioMed Research International 2013, pages 1-12.
Crossref
Ibraheem H. Motabi & John F. DiPersio. (2012) Advances in stem cell mobilization. Blood Reviews 26:6, pages 267-278.
Crossref
Ashanka Beligaswatte, Ian Lewis & Luen Bik To. 2012. Twenty Years of G-CSF. Twenty Years of G-CSF 249 275 .
Stefan Fruehauf & Guido Tricot. 2012. Novel Developments in Stem Cell Mobilization. Novel Developments in Stem Cell Mobilization 165 200 .
L. Bik ToJean-Pierre Levesque & Kirsten E. Herbert. (2011) How I treat patients who mobilize hematopoietic stem cells poorly. Blood 118:17, pages 4530-4540.
Crossref
Chitra Hosing, Veronica Smith, Beverly Rhodes, Kent Walters, Richmond Thompson, Muzaffar Qazilbash, Issa Khouri, Marcos de Lima, Richard J. Balzer, John McMannis, Richard Champlin, Sergio Giralt & Uday Popat. (2011) Assessing the charges associated with hematopoietic stem cell mobilization and remobilization in patients with lymphoma and multiple myeloma undergoing autologous hematopoietic peripheral blood stem cell transplantation. Transfusion 51:6, pages 1300-1313.
Crossref
E Jantunen & S Fruehauf. (2011) Importance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens. Bone Marrow Transplantation 46:5, pages 627-635.
Crossref
Paul Shaughnessy, Miguel Islas-Ohlmayer, Julie Murphy, Maureen Hougham, Jill MacPherson, Kurt Winkler, Matthew Silva, Michael Steinberg, Jeffrey Matous, Sheryl Selvey, Michael Maris & Peter A. McSweeney. (2011) Cost and Clinical Analysis of Autologous Hematopoietic Stem Cell Mobilization with G-CSF and Plerixafor Compared to G-CSF and Cyclophosphamide. Biology of Blood and Marrow Transplantation 17:5, pages 729-736.
Crossref
Stefan Fruehauf & Guido Tricot. (2010) Comparison of Unmobilized and Mobilized Graft Characteristics and the Implications of Cell Subsets on Autologous and Allogeneic Transplantation Outcomes. Biology of Blood and Marrow Transplantation 16:12, pages 1629-1648.
Crossref
Hollie Devine, D. Kathryn Tierney, Kim Schmit-Pokorny & Kathleen McDermott. (2010) Mobilization of Hematopoietic Stem Cells for Use in Autologous Transplantation. Clinical Journal of Oncology Nursing 14:2, pages 212-222.
Crossref
Lindsay L Rosenbeck, Shivani Srivastava & Patrick J Kiel. (2010) Peripheral Blood Stem Cell Mobilization Tactics. Annals of Pharmacotherapy 44:1, pages 107-116.
Crossref
John F. DiPersioIvana N. MicallefPatrick J. StiffBrian J. BolwellRichard T. MaziarzEric JacobsenAuayporn NademaneeJohn McCartyGary BridgerGary Calandra. (2009) Phase III Prospective Randomized Double-Blind Placebo-Controlled Trial of Plerixafor Plus Granulocyte Colony-Stimulating Factor Compared With Placebo Plus Granulocyte Colony-Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for Patients With Non-Hodgkin's Lymphoma. Journal of Clinical Oncology 27:28, pages 4767-4773.
Crossref
W Bensinger, J F DiPersio & J M McCarty. (2009) Improving stem cell mobilization strategies: future directions. Bone Marrow Transplantation 43:3, pages 181-195.
Crossref
Iskra Pusic, Shi Yuan Jiang, Scott Landua, Geoffrey L. Uy, Michael P. Rettig, Amanda F. Cashen, Peter Westervelt, Ravi Vij, Camille N. Abboud, Keith E. Stockerl-Goldstein, Diane S. Sempek, Angela L. Smith & John F. DiPersio. (2008) Impact of Mobilization and Remobilization Strategies on Achieving Sufficient Stem Cell Yields for Autologous Transplantation. Biology of Blood and Marrow Transplantation 14:9, pages 1045-1056.
Crossref
Reem M. Ameen, Salem H. Alshemmari & Dana Alqallaf. (2008) Factors Associated with Successful Mobilization of Progenitor Hematopoietic Stem Cells Among Patients with Lymphoid Malignancies. Clinical Lymphoma and Myeloma 8:2, pages 106-110.
Crossref
H Watanabe, T Watanabe, H Suzuya, Y Wakata, M Kaneko, T Onishi, Y Okamoto, T Abe, Y Kawano, S Kagami & Y Takaue. (2006) Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor. Bone Marrow Transplantation 37:7, pages 661-668.
Crossref
S Akhtar, A Tbakhi, H Humaidan, A El Weshi, M Rahal & I Maghfoor. (2006) ESHAP+fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients. Bone Marrow Transplantation 37:3, pages 277-282.
Crossref
A Perillo, G Ferrandina, L Pierelli, S Rutella, S Mancuso & G Scambia. (2004) Cytokines alone for PBPC collection in patients with advanced gynaecological malignancies: G-CSF vs G-CSF plus EPO. Bone Marrow Transplantation 34:8, pages 743-744.
Crossref
M Karanth, S Chakrabarti, R A Lovell, C Harvey, K Holder, C C McConkey, D McDonald, C D Fegan & D W Milligan. (2004) A randomised study comparing peripheral blood progenitor mobilisation using intermediate-dose cyclophosphamide plus lenograstim with lenograstim alone. Bone Marrow Transplantation 34:5, pages 399-403.
Crossref
Sandra J. Horning & James O. Armitage. 2003. Thomas' Hematopoietic Cell Transplantation. Thomas' Hematopoietic Cell Transplantation 1207 1220 .
. (2001) Current Awareness. Hematological Oncology 19:3, pages 121-128.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.